Nonpediatric Specialties Face Smaller Return Margins for HPV Vaccine Costs
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, July 31, 2023 -- For nonpediatric specialties, return margins for human papillomavirus (HPV) vaccine costs by private payers are small, according to a study published in the July/August issue of the Annals of Family Medicine.
Yenan Zhu, Ph.D., from the Medical University of South Carolina in Charleston, and colleagues compared HPV vaccine cost reimbursement by the private sector across provider specialties in a nationwide sample of HPV vaccine-eligible adolescents. The number of HPV vaccine doses administered by each of 34,247 clinicians was examined during 2017 to 2018, and reimbursement was calculated as the amount paid by the insurer to clinicians to cover the cost of vaccine purchase.
HPV vaccine cost reimbursement was at or above the U.S. Centers for Disease Control and Prevention list price, but was below the recommendations of the American Academy of Pediatrics. The researchers found that net returns from HPV vaccine cost reimbursements were lowest ($0.34/dose) and highest ($5.08/dose) for family physicians and pediatricians, respectively. A $1 increase in return was associated with an increase in HPV vaccine doses administered (0.08 percent for family physicians, 0.06 percent for "other" specialties, and 0.05 percent for pediatricians).
"Family physicians -- who are so critical and important, especially in rural areas where not all patients have access to pediatricians -- are not receiving adequate reimbursement for the HPV vaccine, which is sort of a disincentive for them to offer this critical cancer-preventive vaccine," coauthor Kalyani Sonawane, Ph.D., of the MUSC Hollings Cancer Center in Charleston, said in a statement.
Financial relationships with Merck and Value Analytics Labs were reported.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Primary HPV Screening Intervals Could Be Extended
FRIDAY, May 24, 2024 -- Primary human papillomavirus (HPV) screening intervals could be extended, with the risk for cervical precancer or worse (CIN2+) eight years after negative...
ASCO: HPV Vaccination Positively Affecting More Than Just Cervical Cancer Risk
THURSDAY, May 23, 2024 -- Human papillomavirus (HPV) vaccination is associated with reduced odds of several types of HPV-related cancers, not just cervical cancer, according to a...
Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions
TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.